{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:39:06Z","timestamp":1790786346972,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2018,10]]},"abstract":"\n Background and objectives<\/jats:title>\n The inflammation-driven increase in peritoneal solute transport rate that occurs during long-term peritoneal dialysis is associated with higher mortality, hospitalization, and encapsulating peritoneal sclerosis. Because biocompatible solutions were developed to mitigate these effects, we examined the association with their use and longitudinal peritoneal solute transport rate.<\/jats:p>\n <\/jats:sec>\n \n Design, setting, participants, & measurements<\/jats:title>\n We analyzed subjects from the multinational prospective Global Fluid Study with three or more peritoneal solute transport rate measurements >2 months from the start of peritoneal dialysis. Follow-up was for 7.5 years (median, 2.3 years; interquartile range, 1.8\u20133.6) in biocompatible solutions and 12.8 years (median, 3.2 years; interquartile range, 1.9\u20134.3) for standard solutions. Using a random intercept\/slopes multilevel model, we examined the association of patients using biocompatible solutions and peritoneal solute transport rate over time, adjusting for center effects, dialysate dextrose concentration, baseline dialysate IL-6 concentration, icodextrin use, residual kidney function, and peritonitis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 366 patients, the 71 receiving biocompatible solutions throughout their time on peritoneal dialysis had a mean adjusted dialysate-to-plasma creatinine ratio of 0.67 compared with 0.72 for standard solutions (\n P<\/jats:italic>\n =0.02). With duration of treatment, there was a continuous increase in peritoneal solute transport rate in patients using standard solutions (range, 2 months to 4 years). In contrast, patients using biocompatible solutions had peritoneal solute transport rates that plateaued after 2 years of therapy. These changes in peritoneal solute transport rate were independent of baseline inflammation and time-varying predictors of faster peritoneal solute transport rate. In patients suffering episodes of peritonitis while using standard solutions, there was an associated increase in peritoneal solute transport rate of 0.020 (95% confidence interval, 0.01 to 0.03) per episode, whereas in patients using biocompatible solutions, there was no change in this parameter (\u22120.014; 95% confidence interval, \u22120.03 to <0.01).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n These data suggest that a different temporal pattern in changes in peritoneal solute transport rate occurs during the course of peritoneal dialysis according to solution type and that patients using biocompatible solutions may avoid the increase in solute transport associated with peritonitis.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.02380218","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T10:14:21Z","timestamp":1535710461000},"page":"1526-1533","source":"Crossref","is-referenced-by-count":48,"title":["Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport"],"prefix":"10.2215","volume":"13","author":[{"given":"Emma H.","family":"Elphick","sequence":"first","affiliation":[{"name":"Institute of Applied Clinical Sciences, Keele University, Stoke on Trent, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Teece","sequence":"additional","affiliation":[{"name":"Institute of Applied Clinical Sciences, Keele University, Stoke on Trent, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8805-6962","authenticated-orcid":false,"given":"James A.","family":"Chess","sequence":"additional","affiliation":[{"name":"Renal Unit, Morriston Hospital, Swansea, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Young","family":"Do","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Yeungnam University Hospital, Daegu, South Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Lim","family":"Kim","sequence":"additional","affiliation":[{"name":"Renal Unit, Kyungpook National University Hospital, Daegu, South Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Bahl","family":"Lee","sequence":"additional","affiliation":[{"name":"Hyonam Kidney Laboratory, Soon Chun Hyang University, Seoul, South Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara N.","family":"Davison","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Alberta, Edmonton, Alberta, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2925-4779","authenticated-orcid":false,"given":"Nicholas","family":"Topley","sequence":"additional","affiliation":[{"name":"Wales Kidney Research Unit, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5127-4755","authenticated-orcid":false,"given":"Simon J.","family":"Davies","sequence":"additional","affiliation":[{"name":"Institute of Applied Clinical Sciences, Keele University, Stoke on Trent, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6285-5368","authenticated-orcid":false,"given":"Mark","family":"Lambie","sequence":"additional","affiliation":[{"name":"Institute of Applied Clinical Sciences, Keele University, Stoke on Trent, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,8,31]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/oxfordjournals.ndt.a027318","article-title":"Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis.","volume":"11","author":"Davies","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"341","DOI":"10.5414\/CNP68341","article-title":"Inflammation from sterile dialysis solutions and the longevity of the peritoneal barrier.","volume":"68","author":"Flessner","year":"2007","journal-title":"Clin Nephrol"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1681\/ASN.2006030194","article-title":"Meta-analysis: Peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis.","volume":"17","author":"Brimble","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/ki.2010.186","article-title":"The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made.","volume":"78","author":"Lambie","year":"2010","journal-title":"Kidney Int"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1681\/ASN.2009070694","article-title":"The pathophysiology of the peritoneal membrane.","volume":"21","author":"Devuyst","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/j.1523-1755.2004.00879.x","article-title":"Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.","volume":"66","author":"Mortier","year":"2004","journal-title":"Kidney Int"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1097\/01.ASN.0000086475.83211.DF","article-title":"Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis.","volume":"14","author":"Haas","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1523-1755.2004.00747.x","article-title":"The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.","volume":"66","author":"Williams","year":"2004","journal-title":"Kidney Int"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.mnh.0000441046.13912.1f","article-title":"Does the use of neutral pH, low glucose degradation product peritoneal dialysis fluids lead to better patient outcomes?","volume":"23","author":"Cho","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2215\/CJN.05410514","article-title":"Effect of neutral-pH, low-glucose degradation product peritoneal dialysis solutions on residual renal function, urine volume, and ultrafiltration: A systematic review and meta-analysis.","volume":"10","author":"Yohanna","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1093\/ndt\/gfs314","article-title":"The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: The balANZ trial.","volume":"27","author":"Johnson","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1681\/ASN.2013030314","article-title":"Independent effects of systemic and local peritoneal inflammation on peritoneal dialysis survival.","volume":"24","author":"Lambie","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/ndt\/17.6.1085","article-title":"Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival.","volume":"17","author":"Davies","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/ki.1994.226","article-title":"A prospective study of peritoneal transport in CAPD patients.","volume":"45","author":"Struijk","year":"1994","journal-title":"Kidney Int"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/089686080402400511","article-title":"A comparison of peritoneal equilibration tests performed 1 and 4 weeks after PD commencement.","volume":"24","author":"Johnson","year":"2004","journal-title":"Perit Dial Int"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3747\/pdi.2012.00052","article-title":"The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: The balANZ trial.","volume":"32","author":"Johnson","year":"2012","journal-title":"Perit Dial Int"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1681\/ASN.V1251046","article-title":"Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis.","volume":"12","author":"Davies","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1681\/ASN.V132470","article-title":"Morphologic changes in the peritoneal membrane of patients with renal disease.","volume":"13","author":"Williams","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1681\/ASN.2016010112","article-title":"The current state of peritoneal dialysis.","volume":"27","author":"Mehrotra","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/ndt\/13.4.962","article-title":"Peritoneal solute transport predicts survival on CAPD independently of residual renal function.","volume":"13","author":"Davies","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/089686080602600109","article-title":"Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis.","volume":"26","author":"Pecoits-Filho","year":"2006","journal-title":"Perit Dial Int"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/ndt\/gfp670","article-title":"Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients.","volume":"25","author":"Oh","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ndt\/gfu233","article-title":"Interleukin-6 in renal disease and therapy.","volume":"30","author":"Jones","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1096\/fj.99-1003rev","article-title":"The soluble interleukin 6 receptor: Mechanisms of production and implications in disease.","volume":"15","author":"Jones","year":"2001","journal-title":"FASEB J"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1681\/ASN.2015101169","article-title":"IL-6 trans-signaling links inflammation with angiogenesis in the peritoneal membrane.","volume":"28","author":"Catar","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1111\/j.1523-1755.2004.66021.x","article-title":"Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients.","volume":"66","author":"Davies","year":"2004","journal-title":"Kidney Int"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3747\/pdi.2014.00277","article-title":"The first peritonitis episode alters the natural course of peritoneal membrane characteristics in peritoneal dialysis patients.","volume":"35","author":"van Diepen","year":"2015","journal-title":"Perit Dial Int"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201810000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:08Z","timestamp":1786369328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201810000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.02380218","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,31]]}}}